[Clinical use of arfonad and hygronium aerosols in emergency hypotensive therapy].
During clinical testing of the administration of ganglion-blocking agents by inhalation (175 persons) it was established that drug aerosols of arfonad and hygronium possess high effectiveness, act rapidly, and are relatively safe. The inhalation method of the management of hypertensive crises may find wide use in out-patient practice, under conditions of the admission room, cardiological and resuscitation departments, as well as in obstetrics when controlled hypotension is necessary.
D000328:Adult; D000336:Aerosols; D008725:Bis-Trimethylammonium Compounds / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004630:Emergencies; D005730:Ganglionic Blockers / Q000008:administration & dosage*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D011392:Proline / Q000008:administration & dosage / Q000031:analogs & derivatives*; D012138:Respiratory Therapy; D012881:Skin Temperature / Q000187:drug effects; D014294:Trimethaphan / Q000008:administration & dosage / Q000031:analogs & derivatives*
D000336:Aerosols; D008725:Bis-Trimethylammonium Compounds; D005730:Ganglionic Blockers; C020369:hygronium; D014294:Trimethaphan; C017774:trimethaphan camsylate; D011392:Proline
Klinicheskoe primenenie aérozoleĭ arfonada i gigroniia pri neotlozhnoĭ gipotenzivnoĭ terapii.